Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Iovance Biotherapeutics Inc IOVA

Healthcare Biotechnology
Iovance Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company develops and delivers tumor infiltrating lymphocyte (TIL), therapies for patients with solid tumor cancers. Its lead product candidate, Amtagvi (lifileucel), is a tumor-derived autologous T cell immunotherapy indicated for the treatment of adult patients with unresectable or metastatic melanoma previously... see more

Recent & Breaking News (NDAQ:IOVA)

Mid-Day Market Update: Bed Bath & Beyond Drops On Earnings Miss; DelMar Pharmaceuticals Shares Plunge

Benzinga.com  September 20, 2017

Mid-Morning Market Update: Markets Edge Lower; General Mills Earnings Miss Estimates

Benzinga.com  September 20, 2017

Iovance Biotherapeutics, Inc. Announces Public Offering of Common Stock

GlobeNewswire September 19, 2017

Iovance Biotherapeutics Announces Approval of First Clinical Trial Application by Competent Authority in Netherlands for a Phase 2 Trial of LN-145 for the Treatment of Patients with Cervical Cancer

GlobeNewswire September 13, 2017

Iovance Biotherapeutics Partners with TrakCel for Personalized Patient Product Management

GlobeNewswire September 11, 2017

Iovance Biotherapeutics Enters into a Research Collaboration Focused on Hematologic Malignancies with The Ohio State University Comprehensive Cancer Center

GlobeNewswire September 7, 2017

Iovance Biotherapeutics to Present at Two Upcoming September Conferences

GlobeNewswire September 5, 2017

Mid-Day Market Update: Palo Alto Networks Surges After Strong Q4 Results; Ambarella Shares Plunge

Benzinga.com  September 1, 2017

Iovance Biotherapeutics Announces FDA Fast Track Designation for LN-144 for Treatment of Advanced Melanoma

GlobeNewswire August 31, 2017

Iovance Biotherapeutics to Present Data at Upcoming ESMO 2017 Congress on Tumor-Infiltrating Lymphocyte Treatment for Lymphoma Indications

GlobeNewswire August 31, 2017

Iovance Biotherapeutics Announces First Patient Dosed in C-145-04 Phase 2 Trial in Cervical Cancer

GlobeNewswire August 16, 2017

Iovance Biotherapeutics Appoints Timothy Morris as Chief Financial Officer

GlobeNewswire August 8, 2017

Iovance Biotherapeutics Reports Second Quarter 2017 Financial Results

GlobeNewswire August 1, 2017

Iovance Biotherapeutics to Host Conference Call to Discuss Second Quarter 2017 Financial and Operating Results on Tuesday, August 1, 2017

GlobeNewswire July 25, 2017

Lion Biotechnologies, Inc. Changes Name to Iovance Biotherapeutics, Inc.

GlobeNewswire June 27, 2017